Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
2019 was an average year for medtech M&A. 2020, not so much.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.